Galectin Therapeutics (GALT) Accounts Payables (2010 - 2026)

Galectin Therapeutics' Accounts Payables history runs 17 years deep, the most recent figure standing at $3.1 million for Q1 2026.

• In Q1 2026, Accounts Payables fell 52.23% year-over-year to $3.1 million; the TTM figure through Mar 2026 stood at $3.1 million (down 52.23% YoY), while the FY2025 annual figure was $3.2 million, down 42.63% from the prior year.
• Accounts Payables for Q1 2026 stood at $3.1 million, down from $3.2 million in the prior quarter.
• The five-year high for Accounts Payables was $6.5 million in Q1 2025, with the low at $1.9 million in Q1 2022.
• The 5-year median for Accounts Payables is $3.2 million (2025), against an average of $3.8 million.
• The sharpest annual moves came in 2022 and 2026: Accounts Payables soared 398.95% in 2022, then slumped 52.23% in 2026.
• Galectin Therapeutics' Accounts Payables stood at $3.9 million in 2022, then jumped by 65.32% to $6.4 million in 2023, then fell by 12.05% to $5.7 million in 2024, then plunged by 42.63% to $3.2 million in 2025, then dropped by 3.82% to $3.1 million in 2026.
• Business Quant data shows GALT's Accounts Payables at $3.1 million in Q1 2026, $3.2 million in Q4 2025, and $5.4 million in Q3 2025.